Patents Assigned to ADAPTIVE BIOTECHNOLOGIES CORPORATION
  • Patent number: 9394567
    Abstract: The invention is directed to methods for detecting and quantifying nucleic acid contamination in a tissue sample of an individual containing T cells and/or B cells, which is used for generating a sequence-based clonotype profile. In one aspect, the invention is implemented by measuring the presence and/or level of an endogenous or exogenous nucleic acid tag by which nucleic acid from an intended individual can be distinguished from that of unintended individuals. Endogenous tags include genetic identity markers, such as short tandem repeats, rare clonotypes or the like, and exogenous tags include sequence tags employed to determine clonotype sequences from sequence reads.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: July 19, 2016
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Thomas Asbury, Victoria Carlton, Malek Faham, Stephen C. Macevicz, Martin Moorhead, Thomas Willis, Jianbiao Zheng
  • Patent number: 9279159
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: March 8, 2016
    Assignees: ADAPTIVE BIOTECHNOLOGIES CORPORATION, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Harlan S. Robins, Robert J. Livingston, Jason H. Bielas
  • Publication number: 20160024493
    Abstract: Compositions and methods are disclosed for uniquely tagging each rearranged gene segment that encodes a T cell receptor (TCR) and/or an immunoglobulin (Ig), in a DNA (or mRNA or cDNA reverse transcribed therefrom) sample from lymphoid cells. These and related embodiments permit accurate, high throughput quantification of distinct TCR and/or Ig encoding sequences. Also provided are compositions and methods for quantitatively sequencing the genes that encode both chains of a TCR or Ig heterodimer in a single cell, for example, to characterize the degree of T or B cell clonality in a sample.
    Type: Application
    Filed: March 17, 2014
    Publication date: January 28, 2016
    Applicant: Adaptive Biotechnologies Corporation
    Inventor: Harlan S. Robins
  • Patent number: 9181591
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: November 10, 2015
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Harlan S. Robins, Robert J. Livingston
  • Patent number: 9181590
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: November 10, 2015
    Assignee: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Harlan S. Robins, Robert J. Livingston
  • Patent number: 9150905
    Abstract: Compositions and methods are described for standardizing the DNA amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of DNA templates that contains rearranged lymphoid cell DNA encoding T cell receptors (TCR) or immunoglobulins (IG). The presently disclosed embodiments are useful to overcome undesirable bias in the utilization of a subset of amplification primers, which leads to imprecision in multiplexed high throughput sequencing of amplification products to quantify unique TCR or Ig encoding genomes in a sample. Provided is a composition comprising a diverse plurality of template oligonucleotides in substantially equimolar amounts, for use as a calibration standard for amplification primer sets. Also provided are methods for identifying and correcting biased primer efficiency during amplification.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: October 6, 2015
    Assignee: Adaptive Biotechnologies Corporation
    Inventors: Harlan Saul Robins, Christopher Scott Carlson, Robert J. Livingston, Ryan O. Emerson, Anna M. Sherwood
  • Publication number: 20140186848
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 3, 2014
    Applicants: Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies Corporation
    Inventors: Harlan S. Robins, Robert J. Livingston, Jason H. Bielas
  • Publication number: 20130288237
    Abstract: Compositions and methods are described for highly sensitive quantification of the relative representation of DNA from adaptive immune cells (e.g., T and/or B lymphocytes) in DNA extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (TIL), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 31, 2013
    Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: ADAPTIVE BIOTECHNOLOGIES CORPORATION, FRED HUTCHINSON CANCER RESEARCH CEN
  • Publication number: 20130253842
    Abstract: Methods are described for diagnosis of a lymphoid hematological malignancy in a subject prior to treatment, and for detecting minimal residual disease (MRD) in the subject after treatment for the malignancy, by high throughput quantitative sequencing (HTS) of multiple unique adaptive immune receptor (TCR or Ig) encoding DNA molecules that have been amplified from DNA isolated from blood samples or other lymphoid cell-containing samples. Amplification employs oligonucleotide primer sets designed to amplify CDR3-encoding sequences within substantially all possible human VDJ or VJ combinations. Disease-characteristic adaptive immune receptor clonotypes occur, prior to treatment, at a relative frequency of at least 15-30% of rearranged receptor CDR3-encoding gene regions. Following treatment, persistence of at least one such clonotype at a detectable frequency of at least 10?6 or at least 10?5 receptor CDR3-encoding regions indicates MRD.
    Type: Application
    Filed: December 7, 2012
    Publication date: September 26, 2013
    Applicant: ADAPTIVE BIOTECHNOLOGIES CORPORATION
    Inventors: Anna M. Sherwood, Harlan S. Robins